cas 5580-80-3|| where to buy 2,3,4,5-Tetrafluoroaniline

製品名:2,3,4,5-Tetrafluoroaniline

IUPAC Name:2,3,4,5-tetrafluoroaniline

包装単位	有効在庫	価格（USD）
CM118575-10g	in stock	țƎ
CM118575-25g	in stock	ũȬȺ
CM118575-100g	in stock	ƦțȺ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 5580-80-3 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:5580-80-3; 分子式:C6H3F4N; 融点:-; SMILESコード:NC1=CC(F)=C(F)C(F)=C1F; 密度:

: カタログ番号:CM118575; 分子量:165.09; 沸点:191°C at 760 mmHg; MDL番号:MFCD00025153; 保管方法:Keep in dark place, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Glecirasib; On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.